You are using an outdated browser. Please upgrade your browser to improve your experience and security.

What is AML?

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. In AML, the bone marrow makes abnormal myeloblasts (a type of white blood cell). These abnormal cells are called leukemia cells, or blasts.

Acute leukemia is monitored by measuring the amount of blasts. Because it is a rapidly progressing cancer, the cells divide quickly and the disease may spread fast. As the percentage of blasts increases, the bone marrow is less able to create normal white and red blood cells and platelets.

View more important AML facts.
Bone Marrow From Healthy Patient

Bone marrow from
healthy patient

Bone Marrow From AML Patient

Bone marrow from
patient with AML

Red Blood Cell icon

Red blood cell

White Blood Cell icon

White blood cell

Leukemia Cell icon

Leukemia cell


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of adults with certain types of newly-diagnosed acute myeloid leukemia (AML). These types include patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders, have a specific genetic mutation, or have certain abnormal blood cells (also called AML with myelodysplasia-related changes, AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.